COMMUNIQUÉS West-GlobeNewswire

Interim report for the first three months of 2018

25/04/2018 - 07:57

Read the full announcement in the attached file Attachment 2018_16_Q12018_CompanyAnnouncement_FINAL_EN

Nicox : Ouverture d'un bureau de développement aux Etats-Unis, à Research Triangle Park en Caroline du Nord

25/04/2018 - 07:30

Communiqué de presse Nicox : Ouverture d'un bureau de développement aux Etats-Unis, à Research Triangle Park en Caroline du Nord Les activités de développement de Nicox, en croissance aux Etats-Unis, sont transférées [...]

Nicox: :Opening of U.S. Development Office in Research Triangle Park, North Carolina

25/04/2018 - 07:30

Press Release Nicox: Opening of U.S. Development Office in Research Triangle Park, North Carolina Company to relocate its growing U.S. development operations to the North Carolina biotech hub in Research Triangle Park [...]

Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home

25/04/2018 - 07:16

FocalView is a first-of-its-kind app designed to modernize ophthalmic clinical trials, making them more accessible and flexible Using patients' self-recorded measurements, FocalView aims to enable more sensitive trial [...]

Targovax presentation at ChinaBio Partnering Forum 2018

25/04/2018 - 07:01

Oslo, Norway, 25 April 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumours, have today presented at the ChinaBio Partnering Forum 2018. [...]

Bone Therapeutics SA : Reports Full Year 2017 Results

25/04/2018 - 07:01

Regulated information Bone Therapeutics Reports Full Year 2017 Results Strong clinical progress in ALLOB ® spinal fusion and delayed union trials Leadership team strengthened with appointments of Jean Stéphenne as [...]

Bone Therapeutics SA : Publie ses résultats annuels 2017

25/04/2018 - 07:01

Information réglementée Bone Therapeutics publie ses résultats annuels 2017 Progrès cliniques importants avec ALLOB ® dans la fusion vertébrale et dans les fractures avec retard de consolidation Renforcement de l'équipe [...]

Shire plc : Shire announces revised proposal and extension of PUSU deadline to 8 May 2018

25/04/2018 - 01:11

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT [...]

Compass Cannabis Closes Over-Subscribed Non-Brokered Financing

24/04/2018 - 23:17

CALGARY, Alberta, April 24, 2018 (GLOBE NEWSWIRE) -- 10330698 Canada Ltd. (dba Compass Cannabis Clinic, or “the Company”) is a medical cannabis consultation company with thirty nine clinics that are now open or signed [...]

Psychemedics Announces 1Q Record Revenues and Dividend Increase of 20%

24/04/2018 - 23:15

ACTON, Mass., April 24, 2018 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD ) today announced first quarter financial results for the period ended March 31, 2018. The Company also announced a quarterly [...]

Osiris Therapeutics to Present Clinical and Scientific Studies at Symposium on Advanced Wound Care and Wound Healing Society Spring Conference

24/04/2018 - 22:30

Experts to host a variety of presentations from April 25 – April 29, 2018, in Charlotte, North Carolina COLUMBIA, Maryland, April 24, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (OTC Pink Sheets:OSIR), a leading [...]

ERYTECH Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F

24/04/2018 - 22:30

LYON, France, April 24, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq: ERYP ) , the clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan [...]

ERYTECH annonce le dépôt de son Document de Référence 2017 et de son Form 20-F 2017

24/04/2018 - 22:30

LYON, France, 24 avr. 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq: ERYP ) , société biopharmaceutique de stade clinique développant à partir de sa plateforme propriétaire d’encapsulation de [...]

Flexion Therapeutics to Present Data on ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) at the Academy of Managed Care Pharmacy Annual Meeting 2018

24/04/2018 - 22:30

Post-hoc analysis indicated ZILRETTA provided significant improvements in pain and function in patients with unilateral knee osteoarthritis Abstract receives silver ribbon designation BURLINGTON, Mass., April 24, 2018 ( [...]

Reata Announces New Preclinical Data Demonstrating the Potential of Omaveloxolone in the Treatment of Friedreich’s Ataxia and Other Severe Neurological Diseases

24/04/2018 - 22:15

IRVING, Texas, April 24, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA ) (Reata or Company), a clinical-stage biopharmaceutical company, today announced new preclinical data demonstrating that [...]

Supernus to Host First Quarter 2018 Earnings Conference Call

24/04/2018 - 22:15

ROCKVILLE, Md., April 24, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN ), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central [...]

Aclaris Therapeutics Announces Appointment of Bryan Reasons as a Director and Chairman of the Audit Committee

24/04/2018 - 22:05

WAYNE, Pa., April 24, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS ), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to [...]

Aclaris Therapeutics to Announce First Quarter 2018 Financial Results on May 8, 2018

24/04/2018 - 22:05

WAYNE, Pa., April 24, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS ), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to [...]

AveXis Presents Initial Data from Pivotal U.S. Trial for SMA Type 1 and 24-Month Follow-Up Data from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of Neurology

24/04/2018 - 22:01

– A mean increase in CHOP-INTEND of 17.3 was observed at three months post gene therapy in SMA Type 1 U.S. pivotal trial – – All patients in the therapeutic dose cohort in the Phase 1 trial were alive and event-free at [...]